The oral TYK2 inhibitor for psoriasis will soon be introduced to Korea.

According to industry sources, BMS Korea applied for domestic marketing authorization for its tyrosine kinase 2 (TYK2) inhibitor ‘Sotyktu (deucravacitinib) in Korea.

The drug was approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy by the US FDA.

Sotyktu is the first TYK2 inhibitor to ever be approved in the world (first-in-class), and the first oral drug introduced in 10 years to treat moderate-to-severe plaque psoriasis. The approval is based on results from the Phase III POETYK PSO-1 and POETYK PSO-2 clinical trials, wh